Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney ; volume:18 ; number:1 ; day:3 ; month:10 ; year:2016 ; pages:1-10 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (3.10.2016), 1-10, 12.2016
- Creator
-
Miner, Jeffrey N.
- Contributor
-
Tan, Philip K.
Hyndman, David
Liu, Sha
Iverson, Cory
Nanavati, Payal
Hagerty, David T.
Manhard, Kimberly
Shen, Zancong
Girardet, Jean-Luc
Yeh, Li-Tain
Terkeltaub, Robert
Quart, Barry
SpringerLink (Online service)
- DOI
-
10.1186/s13075-016-1107-x
- URN
-
urn:nbn:de:1111-201611173206
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Miner, Jeffrey N.
- Tan, Philip K.
- Hyndman, David
- Liu, Sha
- Iverson, Cory
- Nanavati, Payal
- Hagerty, David T.
- Manhard, Kimberly
- Shen, Zancong
- Girardet, Jean-Luc
- Yeh, Li-Tain
- Terkeltaub, Robert
- Quart, Barry
- SpringerLink (Online service)
Other Objects (12)
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Gout and uric acid metabolism
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
The renal urate transporter SLC17A1 locus: confirmation of association with gout
The relationship between ferritin and urate levels and risk of gout
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Gout and uric acid metabolism
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
The renal urate transporter SLC17A1 locus: confirmation of association with gout
The relationship between ferritin and urate levels and risk of gout
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Gout and uric acid metabolism
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
The renal urate transporter SLC17A1 locus: confirmation of association with gout
The relationship between ferritin and urate levels and risk of gout
Unraveling the pathological biomineralization of monosodium urate crystals in gout patients
Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study